Lowest Price Guaranteed
Pages
190
Last Updated
June 2025
View Count
5591
The global single cell multi-omics market, valued at USD 3.18 billion in 2024, is expected to reach USD 3.93 billion in 2025 and USD 21.13 billion by 2035, representing a higher CAGR of 18.3% during the forecast period.
 |
Single cell multi-omics refers to the advanced technology that helps to measure multiple data from a single cell simultaneously. This technology enables researchers to gain deep insight into cellular behavior and its regulation. Moreover, single cell multi-omics is also useful to understand the cellular heterogeneity at multiple molecular layers within the cell population.
With a growing shift towards personalized therapeutics and cellular based therapies, single cell multi-omics has gained significant attention from the industrial players and researchers. This advanced single cell analysis technology facilitates the understanding of genomic effect, chromatin dynamics, epigenetic modification and its impact on transcription. The information collected from single cell multi-omics technologies including flow cytometers and cell analysis platforms helps to understand disease progression and development of personalized drugs.
The demand for single cell multiomics has been further driven by the growing shift towards metabolomics, proteomics, and spatial genomics and transcriptomics for the development of personalized drugs. Furthermore, the rising incidence of cancer and chronic conditions across the globe has further necessitated the demand for advanced single cell analysis technologies for early disease diagnosis, prognosis and treatment. As per the report published by National Cancer Institute in May 2024, nearly 14,910 children and adolescents aged (0-19) are diagnosed with cancer.
In order to mitigate the growing concern, several industrial players are taking strategic initiatives for the development of advanced single cell multi-omics technologies and platforms. In June 2024, Mission Bio (global leader in single cell multi-omics solutions) launched Tapestri® (Single Cell Multiple Myeloma Multiomics Solution) specifically designed for research on multiple myeloma and drug development. This latest suite offers deep insight into disease evolution at single cell level.
Similarly, several industrial players are actively exploring the next generation single cell multi-omics technologies and platforms. However, the primary focus on the industrial players will be on innovations, advanced data interpretation and making single cell multi-omics technologies affordable for researchers and hospitals. Driven by the ongoing trend of innovations and rising acceptance across different healthcare verticals, we believe single cell multi-omics market will continue to gain momentum during the forecast period.
The market report highlights the valuable information on industrial players who are presently active across various segments as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | USD 3.93 Billion | |
| Market Size 2035 | USD 21.13 Billion | |
| CAGR (Till 2035) | 18.3% | |
| Type of Product |
|
|
| Type of Omics |
|
|
| Type of Sample |
|
|
| Type of Application |
|
|
| Type of Technique |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the single cell multi-omics market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035.
We have provided informed estimates on the likely evolution of the market for the forecast period. The market analysis also features the likely distribution of the current and forecasted opportunity within the market distributed across various segments such as type of product (instruments and consumables), type of omics (single cell genomics, single cell proteomics, single cell transcriptomics and single cell metabolomics), type of sample (animal samples, human samples, and microbial samples), type of application (cell biology, oncology, neurology and immunology), type of technique (single cell isolation & dispensing and single cell analysis), end user (academic and research institutes, pharmaceutical & biotechnology companies and other end users), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), and leading players.
To account for the uncertainties associated with the development of advanced single cell multi-omics platforms and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of product, the global market is segmented into instruments and consumables. According to our single cell multi-omics market analysis, the instruments segment accounts for the largest market share. It is worth mentioning here that the trend of dominance will continue to remain unchanged during the forecast period. This can be attributed to the fact that instruments such as flow cytometry and microfluidic devices and single-cell RNA sequencing platforms play an important role in the isolation and characterization of cells. Additionally, researchers are using cells analysis instruments for proteomics, genomics and metabolomics which has further fueled the demand for instruments.
However, in the long run, we believe consumables segments is anticipated to register higher CAGR over the forecast period. Consumables such as kits and reagents are required for sample preparation and cell analysis. Rising research on genomics and proteomics will further bolster the demand for consumables.
On the basis of omics type, the global market is categorized into single cell genomics, single cell proteomics, single cell transcriptomics and single cell metabolomics. It is worth mentioning here that currently single-cell genomics accounts for the largest single cell multi-omics market share (over 45%). Single cell genome sequencing platforms and next generation sequencing / NGS kits are widely used in the analysis of cells, contributing to the highest share of this segment.
However, in the long run, single cell metabolomics and single cell transcriptomics segments are likely to grow at a substantial CAGR during the projected period. This can be attributed to the increasing research on metabolomics, and mRNA Vaccine and therapeutics that has necessitated the demand for advanced instruments for cell analysis.
Based on the type of sample, the global market is segmented into animal samples, human samples and microbial samples. According to our single cell multi-omics market report, human samples currently account for the highest share of the market share. This can be attributed to the fact that single cell multi-omics technologies and platforms are widely adopted for human disease diagnosis, research and development of therapeutic drugs. Driven by the ongoing demand for disease diagnosis and drug development for humans, this segment is likely to remain dominant and is estimated to register a higher CAGR during the forecast period.
The global market is categorized based on the type of applications into cell biology, oncology, neurology and immunology. Among these, presently oncology occupies the maximum share (45%) of the market and the trend of dominance is likely to remain unchanged during the single cell multi-omics market forecast period. Single cell multi-omics emerged as a revolutionary approach to identify the biomarkers and helps to gain deeper insight on tumor heterogeneity. Additionally, researchers are exploring single cell multi-omics for understanding metabolic profiles, cancer detection and genetic variability to develop personalized therapies.
However, in the future it is expected that immunology and neurology are the two major segments that are likely to grow at a higher CAGR during the projected period. Single cell multi-omics play a significant role in the development of immunotherapies specifically monoclonal antibody therapeutics to treat a broad range of disease indications. In addition to immunology, single cell multi-omics technologies hold great potential in understanding neural cell characteristics, which is expected to provide a pathway to develop targeted therapies for treating neurodegenerative disorders.
Based on the type of technique, the global single cell multi-omics market is distributed into single-cell isolation & dispensing and single-cell analysis. According to our analysis, single-cell analysis accounts for the largest share (70%) of the market. Single cell analysis techniques are widely adopted for the evaluation of metabolic profiling and transcriptomics in details, which is anticipated to be a key reason for unprecedented growth. Furthermore, this technique is also useful in cancer research, neurological research and disease biomarkers.
However, it is important to highlight here that single cell isolation & dispensing accounts for the highest share of the market. Single cell isolation technique plays a significant role in revealing the cell diversity and heterogenous population of cells to conduct brief research on single cell components on molecular level.
The global market for single cell multi omics is segmented based on the end user into academic and research institutes, pharmaceutical & biotechnology companies and other end users. According to our projection, presently academic institutes and research organizations account for the highest share (61%) of the market. Academic institutes and research organizations are broadly using single cell multi-omics technologies across diverse applications including epigenomics, metabolomics and cellular biology. These technologies help researchers gain better insight into diseases to develop targeted therapies.
In addition to academic institutes and research organizations, pharmaceutical and biotechnology companies are also exploring these technologies to develop novel drugs specifically cell-based therapies and gene therapies, making it another investible segment during the forecast period. Driven by the widespread adoption of single cell multi-omics technologies for understanding disease mechanisms and early diagnosis and designing personalized treatment, this segment is likely to grow at a higher CAGR during the forecast period.
The global market is distributed across different geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. It is worth noting here that presently North America accounts for the highest single cell multi-omics market share (nearly 45%). This dominance is due to the increasing research oncology and chronic diseases by industrial players to develop targeted therapies. Additionally, single cell multi-omics technologies are widely adopted in hospitals for early disease diagnosis and understanding the disease mechanism at molecular level.
However, in Asia-Pacific, the market for single cell multi-omics is expected to grow at a higher CAGR during the forecast period. This is likely to be the growing prevalence of chronic conditions in this region that has underscored the requirement for single cell multi-omics to gain a deep insight into disease and development of tailored therapies.
The “Single Cell Multi-Omics Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities for single cell multi-omics market players. The market research report lays emphasis on the novel industrial players who are presently focusing on the development of single cell multi-omics technologies.
Currently, the market landscape of single cell multi-omics is featuring the presence of several small, mid-sized and large companies. Key companies such as Qiagen, 10X Genomics and Thermo Fisher Scientific are leveraging technological innovations for the development of advanced single cell multi-omics technologies and solutions. In June 2024, Thermo Fisher Scientific launched a new solution at the annual American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, in California. This latest Thermo Scientific Orbitrap™ Astral™ mass spectrometer is helpful for scientists for bringing translational omics research on a large scale. With advanced design that leverage quantitative performance of a triple quadrupole with single cell sensitivity of linear ion trap analyzers, this mass spectrometer can achieve 10X sensitivity to analyze cells.
Similarly, several other market leaders are taking strategic initiatives which we believe will keep the market competitive throughout the forecast period.
The single cell multi-omics industry is witnessing an upward trajectory driven by the growing demand for personalized medicine for the treatment of diseases. Personalized medicines are typically tailored according to the patients’ genetic or molecular profiling by understanding the disease progression. Single cell multi-omics technologies and platforms help to identify cells for understanding disease progression, making isolation and analysis easier.
Moreover, it also helps to identify the biomarkers, which further makes it a valuable tool for the development of personalized therapeutics. Furthermore, the rising demand for advanced analytic tools that aid in early diagnosis of diseases has further bolstered the demand for single cell multi-omics technologies and platform.
Some of the challenges that are hindering market progress during the forecast period include high installation costs and expenses associated with single cell analysis. Notably, the high cost of analyzing single cells analysis may create challenges in the widespread adoption of technologies. Additionally, the limited availability of analysis platforms and data storage challenges may limit the use of single cell multi-omics instruments in hospitals and research areas.
Moreover, lack of trained personnel and occurrence of batch effects during experiments such as cell processing timing, sequencing lanes and chips may affect the data integration from multiple experiments, which further impede market growth.
Some of the promising trends that are expected to propel the market during the forecast period include technological innovations such as advanced computational algorithms and spatial multiomics. Notably, the industrial players are focusing on the integration of advanced AI technology, machine learning and big data analysis as integration algorithm. These technologies enable merging extracted data from different cell omics layers for biological insights.
In addition, spatial multiomics is another key trend in the market that enables researchers to map the molecular profiles within tissue sections without distributing the spatial content of cells and biomolecules. Moreover, industrial players are aiming to develop long-read sequencing techniques such as Oxford Nanopore Technologies that help can utilize different applications such as isoform-level transcriptomics, structural variant detections and de novo genome assembly.
The global single cell multi-omics industry is expected to be valued at USD 3.93 billion in 2025 and is poised to reach USD 21.13 billion by 2035. Driven by the growing demand for advanced analytic technologies for detailed cell analysis, the demand for single cell multi-omics has increased, which is expected to drive the market at a CAGR of 18.3% during the forecast period.
It is worth noting here that the key players of the industry are taking strategic initiatives such as collaborations and partnerships that is expected to be a key driver of the market. For instance, in September 2024, BioSkryb Genomics announced strategic partnership with Human Cell Atlas to offer access to BioSkryb’s next generation single-cell technology (industry-first multiomics product) and computational biology to gain insight into cell biology and diseases. Owing to the ongoing partnerships, we believe this market will continue to grow at a steady rate during the forecast period.
Examples of key companies active in single cell multi-omics industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include 10x Genomics, ANGLE, Agilent Technologies, BD Biosciences, Bio-Rad Laboratories, BGI Genomics, Bruker, CELLENION, CYTENA, Danaher (Beckman Coulter), Illumina, PerkinElmer, Shimadzu, Thermo Fisher Scientific and QIAGEN. This market report includes an easily searchable excel database of all the companies providing single cell multi-omics.
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of single-cell multi-omics. We have outlined some of these recent initiatives below.